Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence, treatment satisfaction, health-related quality of…
- Trial name
- REPOWER (NCT07243002)
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasm
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
- Trial name
- NCT01766297
- Testing
- Proton Radiotherapy
- Where
- 9 sites in United States
- Volunteers
- 132 people
- Sponsor
- Proton Collaborative Group
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.
The goal of this clinical trial is to learn whether letrozole, a hormone therapy drug, is effective in treating early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to nearby lymph nodes in…
- Trial name
- NELOPHER (NCT07394946)
- Testing
- Letrozole
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Cancer Care Hospital & Research Centre Foundation, Lahore
Breast Cancer, Radiation Toxicity
Modulated Accelerated RAdiotherapy in Early Breast Cancer
This trial was a retrospective study on postoperative accelerated hypofractionated IMRT (MARA-1) in patients with early stage breast carcinoma, to compare late toxicity after this treatment and standard fractionated RT delivered…
- Trial name
- NCT03461224
- Testing
- accelerated hypofractionated RT, conventional fractionated RT
- Volunteers
- 447 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Breast Cancer, Ovarian Cancer
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.
- Conditions
- Breast Cancer, Ovarian Cancer, Advanced Cancer
- Trial name
- REVIVAL (NCT02418624)
- Testing
- carboplatin, olaparib
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
This study, titled "Evaluation of the effect of regular physical exercise in women with breast cancer on adjuvant hormone therapy," is a research project designed to see how guided exercise can help women recovering from breast…
- Trial name
- NCT07893327
- Testing
- Supervised exercise program
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer
Randomized trial that compares a personalized digitally-enabled pathway delivered by a mobile application in addition to standard of care vs.
- Trial name
- HOPE (NCT06781996)
- Testing
- multimodal Resilience© digital companion, Standard supportive care
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Neoplasm
Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome
Breast cancer is the most common cancer among women in Norway. In 2016, 3402 new cases were diagnosed (3371 in women). Breast cancer is still the second most common cause of death from cancer among women with 585 breast cancer…
- Trial name
- NCT03761420
- Where
- Norway
- Volunteers
- 1,411 people
- Sponsor
- St. Olavs Hospital
Breast Cancer, HR Positive, HER2 Positive Breast Cancer
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
This is a single-arm, prospective, multicenter, phase II clinical study evaluating the efficacy and safety of a chemotherapy-free neoadjuvant regimen in patients with HR-positive/HER2-positive (HR+/HER2+) early or locally…
- Trial name
- NCT07795424
- Testing
- Culmerciclib, Letrozole, Trastuzumab (TQB211)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shengjing Hospital
Breast Cancer
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- NCT00362973
- Testing
- laboratory biomarker analysis, needle biopsy, positron emission tomography
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
HR+/HER2- Early Breast Cancer
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
- Trial name
- IMPACT PT (NCT07521202)
- Testing
- Standardized patient coaching
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Institut fuer Frauengesundheit
Non Metastatic Breast Cancer
Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy
Many breast cancer patients (BCP) will gain weight during chemotherapy and about 10% of them are able to find back to their initial weight after all treatments are finished.
- Trial name
- NCT01563588
- Testing
- dietaty education, physical training, physiotherapy and SPA cares
- Where
- 2 sites in France
- Volunteers
- 251 people
- Sponsor
- Centre Jean Perrin
Breast Cancer With Low to Intermediate HER2 Expression
Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women…
- Trial name
- POCEB (NCT07630402)
- Testing
- Echocardiogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
ctDNA Monitoring, Breast Cancer
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
The goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer…
- Trial name
- ARCHE (NCT07292207)
- Testing
- Abemaciclib 150 MG Oral Tablet
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Nagoya City University
Breast Cancer
Efficacy of Capecitabine With Adjuvant Radiotherapy in Treatment of Early Stages Breast Cancer (Retrospective Study).
1- Determine the efficacy and safety of concurrent capecitabine and external beam irradiation in patients with early stages breast cancer.
- Trial name
- NCT04815616
- Testing
- Radiotherapy
- Volunteers
- 47 people
- Sponsor
- Assiut University
HER2 + Breast Cancer
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07294534
- Testing
- HLX87+HX22, HLX87 + Pertuzumab, TCbHP
- Volunteers
- 817 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer
Timing of Specific Exercise Therapy After Breast Cancer Surgery: Early Versus Delayed Initiation
This single-center, parallel-group randomized controlled trial (RCT) will compare two timings for initiating specific exercise therapy after breast cancer surgery.
- Trial name
- BEST-Timing (NCT06918184)
- Testing
- Specific Exercise Therapy
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Al Hayah University In Cairo
Breast Cancer
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
- Trial name
- NCT02838225
- Testing
- Docetaxel, Doxorubicin, Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.
- Trial name
- NCT00130533
- Testing
- Capecitabine
- Where
- 48 sites in Spain
- Volunteers
- 876 people
- Sponsor
- Spanish Breast Cancer Research Group